ArticleAdvanced technology in neuroscience2025
Applications of advances in therapeutic electrical stimulation techniques and technologies in precision peripheral nerve repair: a narrative review.
Article in Advanced technology in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Targeted muscle reinnervation surgery modulates apoptosis and synaptic plasticity to improve motor function following tibial nerve injury in rats.Annals of medicine · 2026Article
- Closed-Loop Neuromodulation for Brain Fatigue: From Real-Time Biomarkers to Adaptive Intervention.International journal of molecular sciences · 2026Review
- Neuromodulation Techniques Alleviating Neuropathic Pain by Targeting Microglia: A Narrative Review.Pain and therapy · 2026Review
- Novel Composite Conduits for Long-Distance Peripheral Nerve Repair.Polymer science & technology (Washington, D.C.) · 2026Article
- Advances in electrical stimulation-based therapeutic technologies for sarcopenia prevention and treatment.Bioactive materials · 2026Review
- Injectable chitosan-based hydrogel via in situ gelation modulates the inflammatory microenvironment and facilitates minimally invasive repair of peripheral nerve injury.Materials today. Bio · 2026Article
- Electroacupuncture Modulates Multiple Pathways for Neuroprotection and Neurorepair in Ischemic Stroke.CNS neuroscience & therapeutics · 2026Review
- Activation of the YAP1/pSTAT3/NRP1 axis in peritendinous sensory nerves promotes tendon healing.Science advances · 2026Article
- Early Rehabilitation Versus Conventional Approaches in Post-Traumatic Hand Injuries with Multiple Lesions: Clinical Outcomes and Future Directions.Medicina (Kaunas, Lithuania) · 2025Article
- S-ketamine facilitates motor function recovery after brachial plexus root avulsion and reimplantation in mice.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Peripheral nerve injuries affect large numbers of individuals each year, often resulting in long-term disabilities due to impairments in motor and sensory function. With traditional treatment approaches, including surgical repair and rehabilitation, the most common outcome is incomplete recovery. This is compounded by the absence of FDA-approved medications to enhance nerve regeneration. Recent advances in therapeutic electrical stimulation (TES) techniques have shown promise to improve axonal regrowth and functional recovery. Typically administered perioperatively in a single 1-hour session, TES has demonstrated efficacy in both preclinical studies and small clinical trials by promoting faster and more complete axonal regeneration. To address the limitations of traditional TES, including infection risks or lead displacement, the recent development of bioresorbable nerve stimulator implants introduces a groundbreaking solution. Furthermore, patient-specific factors, including age, sex, medical comorbidities, and genetic variability, notably interact with clinical outcomes and potentially responsiveness to TES. Such genes include the prevalent Val66Met genetic polymorphism in the brain-derived neurotrophic factor gene (rs6265). Carriers of rs6265 have less nerve regeneration, impaired activity-dependent BDNF secretion and a diminished response to TES in preclinical study. This highlights the growing importance of tailoring TES protocols to each patient for optimal outcomes. Looking ahead, the future of TES in PNI treatment will involve the integration of more sophisticated nerve stimulators to deliver tailored TES protocols, with careful consideration given to patient-specific factors and personalized rehabilitation strategies to maximize functional recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.